Last reviewed · How we verify

NCT05423470

Effect of Intermittent Hypoxia on Ischemia-reperfusion Injury in Healthy Individuals

Completed NA Last updated 7 December 2022
What this trial tests

NA trial testing Intermittent hypoxia in Intermittent Hypoxia in 41 participants. Completed in 1 July 2022.

Timeline
30 May 2019
Primary endpoint
30 December 2021
1 July 2022

Quick facts

Lead sponsorUniversity of Texas at Austin
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposeprevention
Enrollment41
Start date30 May 2019
Primary completion30 December 2021
Estimated completion1 July 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Texas at Austin

Who can join

Adults 18 to 80, any sex, with Intermittent Hypoxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the present study is to determine whether intermittent hypoxia protects against ischemia-reperfusion injury in young and older healthy individuals. The investigators hypothesize that intermittent hypoxia will attenuate the reduction in flow-mediated dilation following ischemia-reperfusion injury.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Intermittent hypoxia

Trials testing the same drug.

Other University of Texas at Austin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05423470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing